Business
Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress
Pivotal data from APEX trial in Advanced Systemic Mastocytosis accepted for oral presentation; Cogent’s third oral presentation of pivotal data with bezuclastinib at major medical meetings Preclinical data from selective, potent JAK2 V617F program accepted for poster presentation WALTHAM, Mass. and BOULDER, Colo., May 12, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today anno
About this update from Cogent Biosciences, Inc.
[{"type":"image","alt":"Cogent Biosciences, Inc.","displaySize":"","headline":null,"caption":"Cogent Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":125,"url":"https://media.zenfs.com/en/globenewswire.com/8335c95b9c1a950d92b59f2ace91c141"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/C3g_c01A5xhx1astIu6oTA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NQ--/https://media.zenfs.com/en/globenewswire.com/8335c95b9c1a950d92b59f2ace91c141","width":300,"height":125},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/C3g_c01A5xhx1astIu6oTA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NQ--/https://media.zenfs.com/en/globenewswire.com/8335c95b9c1a950d92b59f2ace91c141","width":300,"height":125}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Pivotal data from APEX trial in Advanced Systemic Mastocytosis accepted for oral presentation; Cogent’s third oral presentation of pivotal data with bezuclastinib at major medical meetings","length":189,"tagName":"p"}]},{"val":[{"type":"text","content":"Preclinical data from selective, potent JAK2 V617F program accepted for poster presentation","length":91,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":280,"olType":false},{"type":"text","content":"WALTHAM, Mass. and BOULDER, Colo., May 12, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced two presentations from the company’s Advanced Systemic Mastocytosis (AdvSM) program, including an oral presentation highlighting the results of the APEX trial, as well as a poster presentation from its emerging JAK2 V617F program at the European Hematology Association (EHA) Congress being held in Stockholm, Sweden, June 11-14, 2026.","length":559,"tagName":"p"},{"type":"text","content":"Details of the presentations are as follows:","length":44,"tagName":"p"},{"type":"text","content":"Bezuclastinib ","length":13,"tagName":"p"},{"type":"text","content":"Oral Presentation","length":17,"tagName":"p"},{"type":"text","content":"Abstract Title: Efficacy and Safety of Bezuclastinib in Patients With Advanced Systemic Mastocytosis: Primary Results From the Apex StudyPresenter: Daniel DeAngelo, M.D., Ph.D., Chief of the Division of Leukemia at the Dana-Farber Cancer Institute a...